Truist Securities Maintains Buy on Corcept Therapeutics, Raises Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Corcept Therapeutics and raised the price target from $65 to $76, indicating confidence in the company's future performance.
September 30, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on Corcept Therapeutics and increased the price target from $65 to $76, suggesting a positive outlook for the company's stock.
The increase in the price target from $65 to $76 by Truist Securities indicates a strong positive sentiment towards Corcept Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100